TRILUMINATE Pivotal - 2-year update EuroPCR 2025, presented by G. Singh
The TRILUMINATE Pivotal trial demonstrated that TriClip™ TEER was superior to medical therapy alone at reducing Heart Failure Hospitalization (HFH) risk at 2 years, while confirming its exceptional safety and quality of life improvement
LEARN MORE:
Related Resources
Valvular Heart Disease Guidelines at a Glance
Demonstrated Outcomes. Life-Changing Intervention
Reduced HF Hospitalisation. Improved Quality of Life
Immediate Relief. Durable Benefits
Tri.Fr 2 years outcomes
Navitor 5-years data from CRT
Tendyne expanded clinical study | PCR LV 2025
EXPAND G4 clinical data release | PCR LV 2025